Head to Head Analysis: Insmed (INSM) versus Its Rivals
Insmed (NASDAQ: INSM) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Insmed to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.
Insider & Institutional Ownership
95.3% of Insmed shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.1% of Insmed shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Insmed has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Insmed’s competitors have a beta of 2.40, meaning that their average stock price is 140% more volatile than the S&P 500.
This is a summary of current recommendations for Insmed and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insmed currently has a consensus price target of $36.71, indicating a potential upside of 11.29%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.87%. Given Insmed’s competitors higher probable upside, analysts plainly believe Insmed has less favorable growth aspects than its competitors.
This table compares Insmed and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Insmed and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Insmed Competitors||$290.27 million||$35.99 million||58.37|
Insmed’s competitors have higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insmed competitors beat Insmed on 8 of the 13 factors compared.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.